Business Context and Reporting Period
Altimmune, Inc. filed a Form 8-K on April 22, 2026, reporting the entry into a material definitive underwriting agreement. The company is a Delaware corporation headquartered in Gaithersburg, Maryland, focused on clinical development. The offering described in the filing closed on April 24, 2026.
Key Financial Metrics and Transaction Details
- Transaction Type: Public offering of common stock and pre-funded warrants.
- Securities Issued: 64,250,000 shares of Common Stock and up to 10,750,000 Pre-Funded Warrants.
- Offering Price: $3.00 per share of Common Stock; $2.999 per Pre-Funded Warrant.
- Net Proceeds: Approximately $211.2 million after deducting underwriting discounts, commissions, and estimated offering expenses.
- Warrant Terms: Common Stock Warrants are exercisable at $3.00 per share. Pre-Funded Warrants have an exercise price of $0.001.
- Liquidity Impact: Proceeds are intended to extend the company's cash runway alongside existing cash, cash equivalents, and marketable securities.
Material Changes and Use of Proceeds
This filing represents a significant capital raise event rather than a periodic financial performance report. The material change is the increase in equity capital and the issuance of warrants. The company intends to use the net proceeds to:
- Advance the clinical development of pemvidutide.
- Fund and prepare for the global pivotal Phase 3 trial in metabolic dysfunction-associated steatohepatitis (MASH).
- Initiate pre-commercial activities for its lead program.
- Support general corporate purposes.
Guidance, Risks, and Contingencies
The filing contains forward-looking statements regarding the anticipated use of capital and cash runway. Management explicitly disclaims any obligation to update these statements. Key risks and contingencies include:
- Market Conditions: Uncertainties related to market conditions affecting the completion of the offering.
- Beneficial Ownership Limitations: Warrant holders are subject to beneficial ownership limitations (initially 4.99% or 9.99%, adjustable up to 19.99% with notice).
- Warrant Expiration: Common Stock Warrants expire on the earlier of the fifth anniversary of issuance or 45 days following a successful Phase 3 data readout for pemvidutide in MASH.
- Listing Status: The Warrants will not be listed on the Nasdaq Global Market or other national securities exchanges.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received versus the estimated $211.2 million.
- Confirm the specific terms of the "Beneficial Ownership Limitation" elections made by major investors.
- Review the updated cash position and runway extension in the next quarterly filing (10-Q).
- Monitor the timeline for the initiation of the global pivotal Phase 3 trial for pemvidutide in MASH.
- Check for any subsequent filings regarding the exercise of Pre-Funded Warrants into common stock.